Cardiac disorder adverse events and serious adverse events (safety set)
| Glycopyrronium +SAL/FP | Tiotropium +SAL/FP | Placebo +SAL/FP | |
|---|---|---|---|
| N=257 | N=258 | N=257 | |
| Cardiac disorders: adverse events | 3 (1.2%) | 10 (3.9%) | 7 (2.7%) |
| Arrhythmia | 1 (0.4%) | 0 | 0 |
| Atrial fibrillation | 1 (0.4%) | 2 (0.8%) | 3 (1.2%) |
| Atrial flutter | 1 (0.4%) | 1 (0.4%) | 0 |
| Ischaemic cardiomyopathy | 1 (0.4%) | 0 | 0 |
| Acute coronary syndrome | 0 | 1 (0.4%) | 1 (0.4%) |
| Angina pectoris | 0 | 1 (0.4%) | 2 (0.8%) |
| Atrioventricular block complete | 0 | 1 (0.4%) | 0 |
| Cardiac failure congestive | 0 | 1 (0.4%) | 0 |
| Left ventricular failure | 0 | 1 (0.4%) | 0 |
| Palpitations | 0 | 3 (1.2%) | 0 |
| Tachyarrhythmia | 0 | 1 (0.4%) | 0 |
| Ventricular fibrillation | 0 | 0 | 1 (0.4%) |
| Cardiac disorders: serious adverse events | 1 (0.4%) | 6 (2.3%) | 4 (1.6%) |
| Atrial flutter | 1 (0.4%) | 1 (0.4%) | 0 |
| Acute coronary syndrome | 0 | 1 (0.4%) | 1 (0.4%) |
| Angina pectoris | 0 | 1 (0.4%) | 1 (0.4%) |
| Atrial fibrillation | 0 | 2 (0.8%) | 1 (0.4%) |
| Atrioventricular block complete | 0 | 1 (0.4%) | 0 |
| Cardiac failure congestive | 0 | 1 (0.4%) | 0 |
| Tachyarrhythmia | 0 | 1 (0.4%) | 0 |
| Ventricular fibrillation | 0 | 0 | 1 (0.4%) |
FP, fluticasone propionate; SAL, salmeterol.